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SI Materials and Methods
Constructs. The pLuc2-KAP-ccdB vector included the chloram-
phenicol resistance gene and the ccdB gene between the attP1 and
attP2 sites in the 3′ UTR of the luc2 reporter gene. The map and
sequence of this construct are shown in Fig. S1 A and C. The
pLuc2-KAP-MCS reporter was generated by inserting the multiple
cloning site of pcDNA3.1(+) (Invitrogen) into pLuc2-KAP-ccdB at
the XhoI and XbaI sites. The map of pLuc2-KAP-MCS is shown in
Fig. S1B. The pcDNA-miR-34a vector was constructed by inserting
the PCR-amplified and EcoRI- and EcoRV-digested human pri-
miR-34a sequence at the EcoRI and EcoRV sites of pcDNA3.1(+)
(Invitrogen). PCR amplification of the human pri-miR-34a se-
quence was conducted by means of HEK293T cell genomic DNA
as a template and miR-34a forward (5′-TTG AAT TCT GCT
GGG GAG AGG CAG GAC A-3′) and reverse (5′-TTG ATA
TCG TGG CGC AGA AGA GCT TCC-3′) primers. We con-
structed 3′-UTR reporters and CDS reporters (Fig. 2F) by ligating
PCR-amplified DNAs into the pLuc2-KAP-MCS vector. Muta-
genesis experiments on FAM76A reporters and GFRA3-CDS re-
porters (Fig. 3 A–D) were carried out by inverse PCR of these
reporters with phosphorylated primers and ligation of the ampli-
cons. Primer sequences used for the inverse PCR are listed in
Table S4. pcDNA-FLAG was constructed by inserting 3×FLAG
sequences into the multiple cloning site of pcDNA3.1(+).
FLAG-tagged GFRA3 vectors (pcDNA-FLAG-GFRA3 or
pcDNA-FLAG-GFRA3-mut) were constructed by inserting PCR-
amplified GFRA3 or mutated GFRA3 into pcDNA-FLAG.
Reporter Library Construction. The MGC plasmid library (63) was
purchased from ATCC. The construction of the reporter plasmid
was conducted using the Gateway system (Invitrogen). Forty
nanograms of the MGC plasmid, 30 ng of pLuc2-KAP-ccdB, and
0.4 μL of BP Clonase II (Invitrogen) were incubated at 25 °C
overnight and then treated with proteinase K at 37 °C for 10 min.
The recombined DNA was transfected into DH5α-competent cells,
and the cells were incubated on LB-kanamycin plates. The trans-
formants were cultured in a LB-ampicillin medium, and the plas-
mids were extracted using the NucleoSpin Multi 96 plus Plasmid
Kit (MACHEREY-NAGEL) or LaboPass Mini (Cosmo Gene-
tech). Quality testing of the plasmids was performed by sequencing
(80 clones) and restriction enzyme digestion (40 clones). Some re-
porter vectors were constructed by inserting PCR-amplified cDNA
into the multiple cloning sites of pLuc2-KAP-MCS. The reporter li-
brary is listed in Dataset S1. Reporter plasmids were diluted to 4 ng/μL
in elution buffer (10 mM Tris·HCl; pH 8.5) in 96-well plates and then
were dispensed into 384-well culture plates (Greiner) at 5 μL per well
using a Multi Dispenser EDR-384SII (Biotec).
Luciferase Assays. Luciferase assays were performed by incubating
20 μL of OPTI-MEM containing 0.4 μL of FuGENE HD, 25 ng of
reporter plasmids, 50 ng of effector plasmids, and 5 ng of pRL-
SV40 for 20 min in 96-well culture plates. Then 293FT cells in
100 μL of DMEM containing 10% of FBS were added to each well
and cultured for 24–36 h. Then, 20 μL of the culture medium with
or without 0.014 μL of a 1-mM wortmannin (Sigma) stock solution
was added into each well (final concentration 100 nM) and in-
cubated in a 5% CO2 incubator at 37 °C for 5 h. For UPF1-
knockdown experiments, 3 pmol of siRNAs [siUPF1 (s11927,
s11928)] or negative control (AM4611; Ambion, Life Technolo-
gies) were transfected with 0.5 μL of RNAiMAX (Invitrogen) after
7 h of transfection of reporters. Luciferase activity was measured
using an ARVO X3 (PerkinElmer) and the Dual-Glo Luciferase
Assay System (Promega).
Cell Culture, Transfection, and Western Blotting. 293FT cells and
MDA-MB-231 cells were maintained in DMEM supplemented
with 10% of FBS. miRNAmimic [miR-34a (MC11030)] or control
(4464058; mirVana) (Thermo) or siRNAs [FAM76A (s47147,
s57749), GFRA3 (s5718, s5719), or negative control (AM4611);
Ambion, Life Technologies] were transfected into MDA-MB-
231 cells using Lipofectamine RNAiMAX (Invitrogen). After 48 h,
total-RNA samples were extracted by means of ISOGEN (Nippon
Gene). For Western blot analysis, pcDNA vectors (pcDNA
or pcDNA-miR-34a and pcDNA-FLAG-GFRA3 or pcDNA-
FLAG-GFRA3-mut) were cotransfected with FuGENE HD into
293FT cells according to the manufacturer’s instructions. After
48 h, the cells were washed with PBS and lysed with radio-
immunoprecipitation assay (RIPA) buffer [50 mM Tris·HCl
(pH 8.0), 150 mM NaCl, 0.5% DOC, 0.1% SDS, 1% Nonidet
P-40]. Proteins in the cell lysates were separated by SDS/PAGE
followed by semidry transfer to a PVDF membrane. Membranes
were blocked for 30 min with Blocking One (Nacalai Tesque),
incubated with an anti-FAM76A (ab90042; Abcam), anti-GFRA3
(ab8028; Abcam), anti-CARKL (ab69920; Abcam), anti-REM2
(ABD37; Merck Millipore), anti–β-actin (A5316; Sigma), or an
anti–FLAG-M2 antibody (Sigma) at 4 °C overnight or at room
temperature for 1 h, rinsed, and then incubated for 1 h with ECL
mouse IgG HRP-conjugated whole antibody (GE Healthcare).
The blot was developed with the ECL Select Western Blotting
Detection Reagent (GE Healthcare). The protein levels are nor-
malized to β-actin levels in each sample.
RNA Isolation, Reverse Transcription, and Quantitative RT-PCR. Total
RNA samples were extracted by means of ISOGEN (Nippon
Gene). Reverse transcription then was carried out using random
primers (Invitrogen) by means of ReverTra Ace (TOYOBO).
Quantitative RT-PCR (qRT-PCR) was run using THUNDER-
BIRD SYBR qPCR Mix (TOYOBO). The primer sequences used
for the real-time PCR are listed in Table S5. The results are
expressed as mRNA levels normalized to GAPDH mRNA ex-
pression in each sample. To determine mRNA levels, at least three
independent RNA samples were analyzed.
Cell Growth Analysis. Cell viability assays were conducted using the
RealTime-Glo MT Cell Viability Assay (Promega). Six picomoles
of miRNA mimics or siRNAs were transfected into MDA-MB-
231 cells (5 × 103 cells per well) with 0.75 μL of Lipofectamine
RNAiMAX and 50 μL of OPTI-MEM in 48-well plates. After
72 h, the medium was changed to a growth medium with MT Cell
Viability Substrate (Promega) and NanoLuc Enzyme (Promega),
and then the cells were cultured for 24 h. Next, luciferase activity
was measured using an ARVO X3 (PerkinElmer). For a colony-
formation assay, 6 pmol of miRNA mimics or siRNAs was trans-
fected into MDA-MB-231 cells (103 cells per well) with 0.75 μL of
Lipofectamine RNAiMAX and 50 μL of OPTI-MEM in a 12-well
plate. After 2 wk, cell colonies were stained with crystal violet and
counted. These experiments were conducted on at least three in-
dependent samples.
Ago2-CLIPAnalysis.CLIPwas performed as described elsewhere (64),
with modifications. Namely, 100 pmol of miR-34a mimic (MC11030;
mirVana; Thermo) or negative control mimic (4464058; mirVana;
Thermo) was transfected into 15% confluent MDA-MB-231 cells in
a 10-cm dish using Lipofectamine RNAiMAX (Invitrogen). After
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60 h, the cells were washed with ice-cold PBS and UV-irradiated
twice at 200 and 400 mJ/cm2 using a UV crosslinker (CL-1000;
UVP). The cells were lysed with PXL buffer (1× PBS, 0.1% SDS,
0.5% deoxycholate, and 0.5% Nonidet P-40), and then we
added RQ1 DNase (final concentration 30 U/mL; Promega)
with incubation for 5 min. After centrifugation, an anti-human
AGO2 mouse monoclonal antibody (4G8; Wako)- or normal
mouse IgG (Santa Cruz)–Dynabeads Protein G (Thermo) com-
plex was added to the supernatants and incubated on a rotator for
2 h at room temperature. The Dynabeads were washed twice
with PXL buffer, high-salt wash buffer (5× PBS, 0.1% SDS,
0.5% deoxycholate, and 0.5% Nonidet P-40), and PNK buffer
(50 mM Tris·HCl pH 7.4, 10 mM MgCl2, and 0.5% Nonidet
P-40), followed by proteinase K treatment, phenol–chloroform
extraction, and ethanol precipitation. The precipitated RNAs
were reverse transcribed with ReverTra Ace (TOYOBO). qRT-
PCR was performed using THUNDERBIRD SYBR qPCR
Mix (TOYOBO). The primer sequences used for the CLIP are
listed in Table S5.
Clinical Samples and Expression Analysis. The archive of the De-
partment of Breast and Endocrine Surgery, Nagoya City Uni-
versity Hospital in Japan, had 200 samples of breast carcinomas
from 2003–2008 available for an mRNA assay. Tissues were snap-
frozen in liquid nitrogen immediately after resection and were
stored at −80 °C until RNA extraction. Informed consent was
obtained before the surgical procedure. OS was defined as the
interval from the date of primary surgery to death from any cause.
The median follow-up period was 6.9 y (range 1–135 mo). This
protocol was approved by the Institutional Review Board of
Nagoya City University Graduate School of Medical Sciences and
conformed to the guidelines of the Declaration of Helsinki.
TaqMan Gene Expression Assays (Applied Biosystems) were
used to measure mRNA expression of GFRA3 and of the house-
keeping gene ACTB. qRT-PCR assays were performed on a 7500
Fast Real-time PCR System (Applied Biosystems). The amplifica-
tion reaction mixture contained 2 μL of cDNA (1–100 ng), 10 μL of
the TaqMan Gene Expression Master Mix (Applied Biosystems),
1 μL of TaqMan Gene Expression Assay Buffer, and 7 μL of RNase-
free water in a total volume of 20 μL. The PCR conditions used for
GFRA3 and ACTB were 50 °C for 2 min, 95 °C for 20 s, and
40 cycles of denaturation at 95 °C for 3 s and annealing with
elongation at 62 °C for 30 s. The samples were amplified in-
dependently in duplicate. The relative concentrations of GFRA3
mRNA were normalized to the ACTB gene as an internal control.
The cutoff value of GFRA3 mRNA was the median in this study.
cDNA was reverse-transcribed from total-RNA samples using
specific miRNA primers from the TaqManMicroRNAAssays and
reagents from the TaqMan MicroRNA Reverse Transcription kit
(Applied Biosystems). The resulting cDNA was amplified by PCR
using TaqMan MicroRNA Assay primers with the TaqMan Uni-
versal PCR Master Mix and was analyzed by means of a 7500 ABI
PRISM Sequence Detector System (Applied Biosystems) according
to the manufacturer’s instructions, as described previously (65).
The relative levels of miR-34a expression were calculated from the
relevant signals by normalization to the signal of U6B miRNA
expression. The name of the assay for miR-34a was “hsa-mir-34a”
(Applied Biosystems). To study the relation between expression
levels of miR-34a and GFRA3 mRNA, Spearman’s rank correla-
tion test was used.
Survival curves were analyzed by the Kaplan–Meier method and
verified by the log-rank test. OS was censored when patients were
alive. The level of significance was set to P < 0.05. Statistical cal-
culations were performed in JMP10 software (SAS Institute, Inc.).
Statistical Analysis. Two-tailed independent Student’s t tests were
used to calculate all P values. Asterisks in the figures indicate
differences with statistical significance: *P < 0.05, **P < 0.01, and
***P < 0.001.
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Fig. S1. Construct maps and sequence. (A) A map of the pLuc2-KAP-ccdB vector. (B) A map of the pLuc2-KAP-MCS vector. (C) Sequence of the pLuc2-KAP-ccdB
vector.
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Fig. S2. A schematic diagram of reporter library construction.
Fig. S3. Size distribution of reporter library cDNAs.
Fig. S4. Preparation of the reporter library system. (A and B) Luciferase assays for the reporters of previously reported miR-34a targets with (B) and without
(A) UPF1 knockdown. (C and D) Luciferase assays for the reporters of previously reported miR-34a targets with (D) and without (C) wortmannin, an NMD inhibitor.
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Fig. S5. An overview of NMD and the mechanism of NMD inhibition by wortmannin. PTCs are detected by the complex of UPF1, eRF1/3, and SMG1, known as
the “surveillance complex” (SURF), and PTC-containing mRNAs are degraded. Wortmannin inhibits SMG1 phosphorylation of UPF1 and thereby inhibits NMD.
Fig. S6. A Venn diagram comparing the miR-34a target genes predicted by TargetScan and the targets that we identified. White text indicates newly
identified targets.
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Fig. S7. Relative mRNA levels of previously identified target genes in MDA-MB-231 cells transfected with the negative control miRNA mimic (Ctrl) or a miR-34a
mimic. *P < 0.05, ***P < 0.001.
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Fig. S8. Screening for miR-146a targets using the reporter library system. (A) A schematic model of the reporter library system for screening for miR-146a
targets. (B) The process of screening for a miR-146a target. (C) Luciferase assays of various reporters in 293FT cells transfected with pcDNA-miR-146a (miR-146a)
or the empty vector (Ctrl). MCS, pLuc2-KAP-MCS (empty reporter). Error bars show SD; **P < 0.01, ***P < 0.001. n = 6.
Fig. S9. Target sites of miR-34a in the three GDNF domains in GFRA3. Red text indicates a target site of miR-34a; black rectangles indicate the α-helix; yellow
highlighting indicates a redundant amino acid sequence of the GDNF domain.
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Fig. S10. CLIP-qPCR analysis (with an anti-AGO2 antibody) of target sequences of FAM76A and GFRA3 in MDA-MB-231 cells overexpressing miR-34a or
miRNA-negative control mimic. *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant.
Fig. S11. Real-time PCR analysis of FAM76A and GFRA3 in MDA-MB-231 cells transfected with siRNA negative control (siNega) or siRNA targeting these genes.
*P < 0.05, **P < 0.01, ***P < 0.001.
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Fig. S12. The expression of GFRA3 and miR-34a in breast cancer tissue samples. The relation between expression levels of miR-34a and GFRA3 in all (A) and
GFRA3+ (B) breast cancer tissue samples.
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Fig. S13. An overview of the high-throughput screening procedure.
Table S1. Values of luciferase activities in Fig. S4A
siNega
Control miR-34a
Reporter Value SD Value SD
MCS 1 0.061 1.081 0.087
SIRT1 1 0.037 0.640 0.044
BCL2 1 0.070 0.823 0.062
CDK6 1 0.031 0.940 0.034
MYC 1 0.048 0.943 0.050
CREB1 1 0.078 0.917 0.066
Ito et al. www.pnas.org/cgi/content/short/1620019114 10 of 12
Table S2. Values of luciferase activities in Fig. S4B
siUPF1-1 siUPF1-2
Control miR-34a Control miR-34a
Reporter Value SD Value SD Value SD Value SD
MCS 1 0.058 1.047 0.050 1 0.050 1.127 0.043
SIRT1 1 0.044 0.640 0.047 1 0.033 0.572 0.039
BCL2 1 0.095 0.773 0.053 1 0.057 0.618 0.039
CDK6 1 0.027 0.894 0.046 1 0.038 0.922 0.048
MYC 1 0.054 0.695 0.020 1 0.075 0.701 0.046
CREB1 1 0.042 0.709 0.023 1 0.094 0.661 0.030
Table S3. Values of luciferase activities in Fig. S4 C and D
Without
wortmannin
With
wortmannin
Control miR-34a Control miR-34a
Reporter Fold SD Fold SD Fold SD Fold SD
MCS 1 0.102 1.190 0.080 1 0.120 1.177 0.104
SIRT1 1 0.086 0.587 0.082 1 0.108 0.546 0.062
BCL2 1 0.027 0.728 0.060 1 0.061 0.705 0.104
CDK6 1 0.049 1.282 0.083 1 0.101 0.950 0.168
MYC 1 0.083 0.916 0.073 1 0.051 0.675 0.081
CREB1 1 0.117 0.849 0.085 1 0.108 0.662 0.028
Table S4. Primer sequences for mutagenesis of reporters
Primer Sequence
FAM76A-3Umut1/2-F TTTGAAAAGATCTATCTTCAGACTTGG
FAM76A-3Umut1/2-R GTTCAGAGGGTTCGCGAGATATATA
FAM76A-3Umut3-F GATTGATTTTAAATTCTCACTGTCCGACTTC
FAM76A-3Umut3-R ACATAAAACAATCAGGAAAGGGGTGG
GFRA3-3Umut-SmaI-F TTTCCCGGGCTGTCCCCGGATCCTGCCGA
GFRA3-3Umut-SmaI-R TTTCCCGGGGCAGGCAGTAGTTTTCCATCCTC
GFRA3-CDSmut1-F CTTCGGTCCCTGCTGACTGCC
GFRA3-CDSmut1-R GCTCCTCTGAGGGTAAAGGGGTG
GFRA3-CDSmut2-F CCTCAGGCAGCTGCTCACTTTCTTC
GFRA3-CDSmut2-R CAGACGTGGCGCTGACAATGGG
GFRA3-CDSmut3-F GACATCCTAGGAACTTGTGCAACAG
GFRA3-CDSmut3-R CATGGGATGACAATGGGTCTGG
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Table S5. Primer sequences for real-time PCR and CLIP
Primer Sequence
FAM76A F GGAACGCCCAAACCTTGTCAG
FAM76A R GTGTGCACAGCCAGCACAGC
GFRA3 F CGCATGAAGAACCAGGTTGCC
GFRA3 R GAGGCAGAGGTCTGAGTCTG
CARKL F GAGCTGTTAGCCACCTGGTC
CARKL R GGACTTCAGGAACTCTGGGC
REM2 F GGACACAGAAACCACAGCACTC
REM2 R GACAGGCATACTGCCTCTTCG
SIRT1 F CTGACTTCAGGTCAAGGGATGG
SIRT1 R GAGATGGCTGGAATTGTCCAGG
SEMA4B F GACCCCTACTGTGCTTGGAG
SEMA4B R GGGACACAACCGAAGACGCG
BCL2 F AGAGCGTCAACCGGGAGATG
BCL2 R CAAACAGAGGCCGCATGCTG
MYB F GCAGTGACGAGGATGATGAGG
MYB R CCATTCTGTTCCACCAGCTTCTTC
CREB1 F GGCCGTGAACGAAAGCAGTG
CREB1 R GCAATCTGTGGCTGGGCTTG
CSF1R F GTGCTCAGCCAGCAGCGTTG
CSF1R R TGCTGGCCACGCAGGAGTAG
MYC F GCCCATTTGGGGACACTTCC
MYC R GCACCGAGTCGTAGTCGAGG
LEF1 F GCACAAACCTCTCAGGAGCC
LEF1 R GATGTTCTCGGGATGGGTGG
GAPDH F CCTGGTCACCAGGGCTGC
GAPDH R CGCTCCTGGAAGATGGTGATG
FAM76A CLIP-1 F CCTGCCATACCCATGAGCAAAC
FAM76A CLIP-1 R GCCTCTTCCATTATACCAAGTCTGAAG
FAM76A CLIP-2 F GGGCAGAAAGCAAGGTTGTCC
FAM76A CLIP-2 R GAAGTGGCAGTGTGAGAATTTAAAATCAATC
GFRA3 CLIP-1 F CTGGATTCCTGCACCTCTAGC
GFRA3 CLIP-1 R CTGAGTTGCTGTGCTGCCTC
GFRA3 CLIP-2 F GACAAGTGTGACCGGCTGCG
GFRA3 CLIP-2 R GAAAGTGAGCAGCTGCCTGAG
GFRA3 CLIP-3 F GCTTTGCAGATCACGCCTGG
GFRA3 CLIP-3 R CATCTGGACTGCTCTGTTGCAC
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